Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. It damages the myelin sheath, the material that surrounds and protects your nerve cells. This damage slows down or blocks messages between your brain and your body, leading to the symptoms of MS. They can include
- Visual disturbances
- Muscle weakness
- Trouble with coordination and balance
- Sensations such as numbness, prickling, or "pins and needles"
- Thinking and memory problems
No one knows what causes MS. It may be an autoimmune disease, which happens when your body attacks itself. Multiple sclerosis affects woman more than men. It often begins between the ages of 20 and 40. Usually, the disease is mild, but some people lose the ability to write, speak or walk. There is no cure for MS, but medicines may slow it down and help control symptoms. Physical and occupational therapy may also help.
Is there any treatment?
What is the prognosis?
What research is being done?
Clinical Trials
Organizations
Related NINDS Publications and Information
Publicaciones en Español
Additional resources
What is Multiple Sclerosis?
An unpredictable disease of the central nervous system, multiple sclerosis (MS) can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted. Many investigators believe MS to be an autoimmune disease -- one in which the body, through its immune system, launches a defensive attack against its own tissues. In the case of MS, it is the nerve-insulating myelin that comes under assault. Such assaults may be linked to an unknown environmental trigger, perhaps a virus.
Most people experience their first symptoms of MS between the ages of 20 and 40; the initial symptom of MS is often blurred or double vision, red-green color distortion, or even blindness in one eye. Most MS patients experience muscle weakness in their extremities and difficulty with coordination and balance. These symptoms may be severe enough to impair walking or even standing. In the worst cases, MS can produce partial or complete paralysis. Most people with MS also exhibit paresthesias, transitory abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations. Some may also experience pain. Speech impediments, tremors, and dizziness are other frequent complaints. Occasionally, people with MS have hearing loss. Approximately half of all people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and poor judgment, but such symptoms are usually mild and are frequently overlooked. Depression is another common feature of MS.
Is there any treatment?
There is as yet no cure for MS. Many patients do well with no therapy at all, especially since many medications have serious side effects and some carry significant risks. However, three forms of beta interferon (Avonex, Betaseron, and Rebif) have now been approved by the Food and Drug Administration for treatment of relapsing-remitting MS. Beta interferon has been shown to reduce the number of exacerbations and may slow the progression of physical disability. When attacks do occur, they tend to be shorter and less severe. The FDA also has approved a synthetic form of myelin basic protein, called copolymer I (Copaxone), for the treatment of relapsing-remitting MS. Copolymer I has few side effects, and studies indicate that the agent can reduce the relapse rate by almost one third. An immunosuppressant treatment, Novantrone (mitoxantrone), is approved by the FDA for the treatment of advanced or chronic MS.
One monoclonal antibody, natalizumab (Tysabri), was shown in clinical trials to significantly reduce the frequency of attacks in people with relapsing forms of MS and was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2004. However, in 2005 the drug’s manufacturer voluntarily suspended marketing of the drug after several reports of significant adverse events. In 2006, the FDA again approved sale of the drug for MS but under strict treatment guidelines involving infusion centers where patients can be monitored by specially trained physicians.
While steroids do not affect the course of MS over time, they can reduce the duration and severity of attacks in some patients. Spasticity, which can occur either as a sustained stiffness caused by increased muscle tone or as spasms that come and go, is usually treated with muscle relaxants and tranquilizers such as baclofen, tizanidine, diazepam, clonazepam, and dantrolene. Physical therapy and exercise can help preserve remaining function, and patients may find that various aids -- such as foot braces, canes, and walkers -- can help them remain independent and mobile. Avoiding excessive activity and avoiding heat are probably the most important measures patients can take to counter physiological fatigue. If psychological symptoms of fatigue such as depression or apathy are evident, antidepressant medications may help. Other drugs that may reduce fatigue in some, but not all, patients include amantadine (Symmetrel), pemoline (Cylert), and the still-experimental drug aminopyridine. Although improvement of optic symptoms usually occurs even without treatment, a short course of treatment with intravenous methylprednisolone (Solu-Medrol) followed by treatment with oral steroids is sometimes used.
What is the prognosis?
A physician may diagnose MS in some patients soon after the onset of the illness. In others, however, doctors may not be able to readily identify the cause of the symptoms, leading to years of uncertainty and multiple diagnoses punctuated by baffling symptoms that mysteriously wax and wane. The vast majority of patients are mildly affected, but in the worst cases, MS can render a person unable to write, speak, or walk. MS is a disease with a natural tendency to remit spontaneously, for which there is no universally effective treatment.
What research is being done?
The National Institute of Neurological Disorders and Stroke (NINDS) and other institutes of the National Institutes of Health (NIH) conduct research in laboratories at the NIH and also support additional research through grants to major medical institutions across the country. Scientists continue their extensive efforts to create new and better therapies for MS. One of the most promising MS research areas involves naturally occurring antiviral proteins known as interferons. Beta interferon has been shown to reduce the number of exacerbations and may slow the progression of physical disability. When attacks do occur, they tend to be shorter and less severe. In addition, there are a number of treatments under investigation that may curtail attacks or improve function. Over a dozen clinical trials testing potential therapies are underway, and additional new treatments are being devised and tested in animal models.
In 2001, the National Academies/Institute of Medicine, a Federal technical and scientific advisory agency, prepared a strategic review of MS research. To read or download the National Academies/Institute of Medicine report, go to: "Multiple Sclerosis: Current Status and Strategies for the Future."
NIH Patient Recruitment for Multiple Sclerosis Clinical Trials
|
Multiple
Sclerosis
Association of
America 706 Haddonfield Road Cherry Hill, NJ 08002 webmaster@msaa.com http://www.msassociation.org Tel: 856-488-4500 800-532-7667 Fax: 856-661-9797 |
Multiple
Sclerosis
Foundation 6350 North Andrews Avenue Ft. Lauderdale, FL 33309-2130 support@msfocus.org http://www.msfocus.org Tel: 954-776-6805 888-MSFOCUS (673-6287) Fax: 954-351-0630 |
|
Accelerated
Cure Project for
Multiple
Sclerosis 300 Fifth Avenue Waltham, MA 02451 info-ninds08@acceleratedcure.com http://www.acceleratedcure.org Tel: 781-487-0008 Fax: 781-487-0009 |
National
Multiple
Sclerosis
Society 733 Third Avenue 3rd Floor New York, NY 10017-3288 nat@nmss.org http://www.nationalmssociety.org Tel: 212-986-3240 800-344-4867 (FIGHTMS) Fax: 212-986-7981 |
|
American
Autoimmune
Related Diseases
Association 22100 Gratiot Avenue Eastpointe, MI 48201-2227 aarda@aarda.org http://www.aarda.org Tel: 586-776-3900 800-598-4668 Fax: 586-776-3903 |
National
Rehabilitation
Information
Center (NARIC) 4200 Forbes Boulevard Suite 202 Lanham, MD 20706-4829 naricinfo@heitechservices.com http://www.naric.com Tel: 301-459-5900/301-459-5984 (TTY) 800-346-2742 Fax: 301-562-2401 |
|
Clearinghouse
on Disability
Information Special Education & Rehabilitative Services Communications & Customer Service Team 550 12th Street, SW, Rm. 5133 Washington, DC 20202-2550 http://www.ed.gov/about/ offices/list/osers Tel: 202-245-7307 202-205-5637 (TTD) Fax: 292024507636 |
National
Ataxia
Foundation (NAF) 2600 Fernbrook Lane North Suite 119 Minneapolis, MN 55447-4752 naf@ataxia.org http://www.ataxia.org Tel: 763-553-0020 Fax: 763-553-0167 |
|
National
Organization for
Rare Disorders (NORD) P.O. Box 1968 (55 Kenosia Avenue) Danbury, CT 06813-1968 orphan@rarediseases.org http://www.rarediseases.org Tel: 203-744-0100 Voice Mail 800-999-NORD (6673) Fax: 203-798-2291 |
Well Spouse
Association 63 West Main Street Suite H Freehold, NJ 07728 info@wellspouse.org http://www.wellspouse.org Tel: 800-838-0879 732-577-8899 Fax: 732-577-8644 |
|
Paralyzed
Veterans of
America (PVA) 801 18th Street, NW Washington, DC 20006-3517 info@pva.org http://www.pva.org Tel: 202-USA-1300 (872-1300) 800-424-8200 Fax: 202-785-4452 |
-
Multiple
Sclerosis: Hope
Through Research
Multiple Sclerosis (MS) information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS). -
Neurological Diagnostic Tests and Procedures
Fact sheet on neurological diagnosis and testing, prepared by the National Institute of Neurological Disorders and Stroke (NINDS).
-
Small Trial Shows Daclizumab Add-On Therapy Improves Multiple Sclerosis Outcome
May 2004 press release on a clinical trial showing improved patient outcome after use of the drug daclizumab. -
Old Drug, New Use: New Research Shows Common Cholesterol-Lowering Drug Reduces Multiple Sclerosis Symptoms in Mice
January 2003 news summary on studies suggesting that statin drugs may be useful for multiple sclerosis. -
Brain Produces New Cells in Multiple Sclerosis
February 2002 news summary on brain repair in multiple sclerosis. -
Biomarkers in Multiple Sclerosis - Workshop Summary
Biomarkers in Multiple Sclerosis - Workshop Summary -
Genetics and Multiple Sclerosis: Future Prospects Workshop
Genetics and Multiple Sclerosis: Future Prospects Workshop -
Multiple Sclerosis and Chemokines: Prospects for Therapeutic and Prophylactic Intervention
Health Disparities Working Group Meeting: Cognitive and Emotional Health Multiple Sclerosis and Chemokines: Prospects for Therapeutic and Prophylactic Intervention -
NINDS Seeks Patients with Multiple Sclerosis
Lay-language descriptions of new program announcements and clinical trials seeking patient volunteers. -
NINDS Accepts Organ Donations for Multiple Sclerosis Research
Lay-language descriptions of new program announcements and clinical trials seeking patient volunteers.
Prepared by:
Office of Communications
and Public Liaison
National Institute of
Neurological Disorders
and Stroke
National Institutes of
Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated December 01, 2008
